Mark L. Ratner
The acquisition of Clarient Inc., a specialist oncology lab, last October by GE Healthcare, a division of
What's Fueling The Recent Diagnostics Dealmaking?
Listen to this article
A variety of new players have become active dealmakers around personalized medicine diagnostics tests and services. One way to put these deals in context is to view the acquired assets through the lens of how they are to be deployed. To a large extent, the transactions are being driven by the interests of drugmakers, which are seeking new tools to assist them in clinical trials, thus creating more opportunity for the acquirers to offer clinical development services.
Candid conversations with C-suite leaders.
More from Business Strategy
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
- • By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.